Vadim Levin, MD
Clinical Cardiac Electrophysiology · Chesapeake, VANPI 1073569158
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 73.5% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $7,431 and has fallen 94.1% since, to $436 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in VA, where the typical reported total is $19,771.
Across 220 payments — averaging $62.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$10K
- Pfizer$881
- Medtronic$613
- Johnson & Johnson$491
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$254
- Abbott$231
- plus $1K from 17 others
Across 36 payments — averaging $1011.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$36K
What the payments were for
- Speaking & faculty fees$4,00029%
- Travel & lodging$3,36324%
- Food & beverage$6,46247%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 71 | $10,164 |
| Pfizer | 39 | $881 |
| Medtronic(2 entities) | 25 | $613 |
| Johnson & Johnson | 18 | $491 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $254 |
| Abbott | 3 | $231 |
| E.r. Squibb & Sons, L.L.C. | 11 | $193 |
| Biosense Webster, Inc. | 6 | $182 |
| Atricure, Inc. | 6 | $174 |
| Merck | 6 | $100 |
| Boehringer Ingelheim | 4 | $84 |
| Sanofi-aventis U.S. LLC | 5 | $81 |
| Novartis | 3 | $61 |
| AstraZeneca | 3 | $56 |
| Preventice Services, LLC | 2 | $51 |
| Alnylam Pharmaceuticals Inc. | 2 | $41 |
| Corcym Inc | 1 | $35 |
| Lantheus Medical Imaging, Inc. | 2 | $32 |
| Chiesi USA, Inc. | 1 | $26 |
| Novo Nordisk | 1 | $25 |
| Amgen | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$4,000
- RHYTHMIA$1,619
- GENERAL - THERAPIES$1,385
- WATCHMAN Access System$212
- Farapulse$128
- XARELTO$124
- CardioMEMS HF System$123
- WATCHMAN FLX$114
- COBALT DR MRI SURESCAN$110
How this compares
$13,825 in reported general payments places this provider in the 35th percentile of 90 clinical cardiac electrophysiology providers in Virginia.
See all clinical cardiac electrophysiology providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 648 | $797,637 |
| XareltoRivaroxaban | 193 | $235,060 |
| EntrestoSacubitril/Valsartan | 73 | $112,590 |
| Dofetilide | 252 | $57,744 |
| MultaqDronedarone Hcl | 54 | $56,430 |
| FarxigaDapagliflozin Propanediol | 43 | $44,999 |
| JardianceEmpagliflozin | 30 | $27,486 |
| Candesartan Cilexetil | 257 | $24,398 |
| Metoprolol Succinate | 764 | $16,370 |
| Nebivolol Hcl | 118 | $7,748 |
| Valsartan | 159 | $7,174 |
| Amiodarone Hcl | 145 | $7,048 |
| Flecainide Acetate | 132 | $5,564 |
| Doxazosin Mesylate | 286 | $4,504 |
| Eplerenone | 69 | $4,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $881 | $797,637648 claims |
| Johnson & JohnsonXarelto | $491 | $235,060193 claims |
| NovartisEntresto | $61 | $112,59073 claims |
| Sanofi-aventis U.S. LLCMultaq | $81 | $56,43054 claims |
| AstraZenecaFarxiga | $56 | $44,99943 claims |
| Boehringer IngelheimJardiance | $84 | $27,48630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 90 clinical cardiac electrophysiology providers in Virginia.
Other clinical cardiac electrophysiology in Chesapeake
- Venkat IyerChesapeake$49K
- Kenneth EllenbogenRichmond$360K
- Brett AtwaterFairfax$319K
- Oliver MonfrediCharlottesville$231K
- Peem LorvidhayaFredericksburg$230K
- Erich KiehlNewport News$181K
- Emmanuel EkanemWinchester$132K
- Pamela MasonCharlottesville$130K
- Ajay PillaiRichmond$129K
- Stephen GaetaFairfax$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.